A robust RNAi nanoplatform for precise activation of cGAS-STING pathway and effective immune checkpoint blockade to potentiate cancer immunotherapy.

Activation of cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-interferon gene stimulator (STING) pathway has demonstrated significant potential in cancer treatment due to its crucial role in bridging the innate and adaptive immunity. However, clinical attempts of current cGAS-STING activating approaches remain challenged because of their undesired adverse effects and low therapeutic efficacy. We herein developed a new and robust immunostimulatory RNA interfering (RNAi) nanoplatform to potentiate breast cancer (BCa) immunotherapy through precise activation of cGAS-STING pathway and effective immune checkpoint blockade. This nanoplatform comprises the electrostatic complexes of small interfering RNA (siRNA) targeting oncogene coactivator-associated arginine methyltransferase 1 (Carm1) and metformin prodrug. Using orthotopic and metastatic BCa tumors, we demonstrated this nanoplatform could suppress the proliferation of BCa cells via siRNA-mediated Carm1 silencing and down-regulate programmed death-ligand 1 (PD-L1) expression via metformin-mediated ubiquitin-proteasome degradation. More importantly, due to the important role of oncogene Carm1 in repairing damaged double stand DNA (dsDNA), Carm1 silencing could specifically enhance the accumulation of damaged dsDNA and cytosolic release of dsDNA fragments to precisely activate the cGAS-STING pathway in BCa cells, which could thus promote their expression and secretion of interferon-β (IFN-β) to induce a significant inhibition of BCa tumor growth via leveraging both the innate and adaptive immunity.

• Publication year

  2026

• Venue

  Journal of Controlled Release

• Publication date

  2026-02-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1016/j.jconrel.2026.114690PMID 41655906
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications

  2025cited by this paper
• Modulating lipid metabolism by nanoparticles (NPs)-mediated ACSL3 silencing to inhibit hepatocellular carcinoma growth and metastasis

  2025cited by this paper
• Nanoparticles (NPs)-mediated silencing of GSTP1 expression to reverse chemoresistance for effective breast cancer therapy.

  2025cited by this paper
• Regulation of cGAS–STING signalling and its diversity of cellular outcomes

  2025cited by this paper
• Bioengineering strategies to optimize STING agonist therapy

  2025cited by this paper
• Tumor-targeting nanocarriers amplified immunotherapy of cold tumors by STING activation and inhibiting immune evasion

  2025cited by this paper
• Dual‐Responsive Immunomodulatory RNAi Nanoplatform for Effective Immune Checkpoint Blockade and Enhanced Cancer Immunotherapy

  2025cited by this paper
• The balance of STING signaling orchestrates immunity in cancer

  2024cited by this paper
• Principles and therapeutic applications of adaptive immunity.

  2024cited by this paper
• Universal STING mimic boosts antitumour immunity via preferential activation of tumour control signalling pathways

  2024cited by this paper
• Precisely Activating cGAS‐STING Pathway with a Novel Peptide‐Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy

  2024cited by this paper
• CARM1 drives triple-negative breast cancer progression by coordinating with HIF1A

  2024cited by this paper
• Nanoparticle-mediated efficient up-regulation of GSDMD-N to induce pyroptosis and enhance NK cell-based cancer immunotherapy.

  2024cited by this paper
• Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform ‘cold’ tumors into ‘hot’ tumors

  2024cited by this paper
• Hybrid nanoparticle–mediated simultaneous ROS scavenging and STING activation improve the antitumor immunity of in situ vaccines

  2024cited by this paper
• Metformin-associated lactic acidosis: a serious complication of a common drug

  2024cited by this paper
• Metal-based nanoparticles promote the activation of cGAS-STING pathway for enhanced cancer immunotherapy

  2024cited by this paper
• Targeting activation of cGAS-STING signaling pathway by engineered biomaterials for enhancing cancer immunotherapy

  2024cited by this paper
• Manganese-Based Immunostimulatory Metal-Organic Framework Activates the cGAS-STING Pathway for Cancer Metalloimmunotherapy.

  2023cited by this paper
• Remodeling of Mitochondrial Metabolism by a Mitochondria-Targeted RNAi Nanoplatform for Effective Cancer Therapy.

  2023cited by this paper
• Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?

  2023cited by this paper
• Harnessing cGAS‐STING Pathway for Cancer Immunotherapy: From Bench to Clinic

  2022cited by this paper
• Cellular functions of cGAS-STING signaling.

  2022cited by this paper
• Radiation therapy promotes hepatocellular carcinoma immune-cloaking via PD-L1 upregulation induced by cGAS-STING activation.

  2022cited by this paper
• Overcoming hurdles in cancer immunotherapy

  2021cited by this paper
• Understanding and treating the inflammatory adverse events of cancer immunotherapy.

  2021cited by this paper
• CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor cells and T cells.

  2021cited by this paper
• Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.

  2021cited by this paper
• Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy

  2021cited by this paper
• Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer.

  2020cited by this paper
• Oxidative Stress in Cancer.

  2020cited by this paper
• Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

  2019cited by this paper
• Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

  2019cited by this paper
• Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden

  2019cited by this paper
• A Conserved PLPLRT/SD Motif of STING Mediates the Recruitment and Activation of TBK1

  2019cited by this paper
• Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.

  2018cited by this paper
• CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity

  2018cited by this paper
• The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer

  2018cited by this paper
• Anti-tumor role of metformin

  2018cited by this paper
• Cancer immunotherapy using checkpoint blockade

  2018cited by this paper
• Cyclic di-GMP: second messenger extraordinaire

  2017cited by this paper
• Elements of cancer immunity and the cancer–immune set point

  2017cited by this paper
• Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing

  2016cited by this paper
• Releasing the Brakes on Cancer Immunotherapy.

  2015cited by this paper
• Control of adaptive immunity by the innate immune system

  2015cited by this paper
• STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

  2014cited by this paper
• CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis.

  2014cited by this paper
• Convenient microwave-assisted synthesis of lipophilic sulfenamide prodrugs of metformin.

  2013cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway

  2013cited by this paper
• Protein arginine methyltransferases and cancer

  2012cited by this paper
• Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

  2011cited by this paper
• Clinical Pharmacokinetics of Metformin

  2011cited by this paper
• Differential CARM1 expression in prostate and colorectal cancers

  2010cited by this paper
• Protein arginine methylation in mammals: who, what, and why.

  2009cited by this paper
• Enzymatic Activity Is Required for the in Vivo Functions of CARM1*

  2009cited by this paper
• The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption.

  2009cited by this paper
• The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing.

  2007cited by this paper

• No citing papers are available for this paper.